Table 1.
Clinical characteristics of the men diagnosed with prostate cancer (PrCa) in the full cohort and in the genotyped subcohort.
| PrCa in full cohort (n = 208) | PrCa in subcohort (n = 126) | |||
|---|---|---|---|---|
| Age at diagnosis: median (range) | 73 | (57-83.0) | 75 | (59-82.0) |
| Diagnosis confirmed by: n (%) | ||||
| Histology | 164 | (78.8) | 112 | (88.9) |
| Cytology | 33 | (15.9) | 11 | (8.7) |
| Clinical examination only | 3 | (1.4) | 1 | (0.8) |
| Information missing | 8 | (3.8) | 2 | (1.6) |
| Diagnosis suspected from: n(%) | ||||
| PSA Screening | 2 | (1.0) | 2 | (1.6) |
| LUTS** | 127 | (61.1) | 85 | (67.5) |
| Other urological or skeletal symptoms | 33 | (15.9) | 18 | (14.3) |
| Incidentally discovered† | 15 | (7.2) | 10 | (7.9) |
| Other | 7 | (3.4) | 6 | (4.8) |
| Information missing | 24 | (11.5) | 5 | (4.0) |
| PSA-level***, ng/mL n (%) | ||||
| ≤4 | 8 | (3.8) | 6 | (4.8) |
| 4.1-10 | 24 | (11.5) | 18 | (14.3) |
| 10.1-20 | 31 | (14.9) | 25 | (19.8) |
| 20.1-100 | 41 | (19.7) | 33 | (26.2) |
| > 100 | 23 | (11.1) | 14 | (11.1) |
| Information missing | 81 | (38.9) | 30 | (23.8) |
| T-stage‡, n (%) | ||||
| T0/T1ab | 28 | (13.5) | 20 | (15.9) |
| T1c | 25 | (12.0) | 19 | (15.1) |
| T2 | 89 | (42.8) | 55 | (43.7) |
| T3-4 | 47 | (22.6) | 27 | (21.4) |
| TX/Information Missing | 19 | (9.1) | 5 | (4.0) |
| N-stage‡, n (%) | ||||
| N0 | 32 | (15.4) | 22 | (17.5) |
| N1 | 12 | (5.8) | 5 | (4.0) |
| NX | 142 | (68.3) | 90 | (71.4) |
| Information missing | 22 | (10.6) | 9 | (7.1) |
| M-stage‡in combination with PSA, n (%) | ||||
| M0 | 88 | (42.3) | 61 | (48.4) |
| MX, PSA ≤20 | 11 | (5.3) | 11 | (8.7) |
| MX, 20 < PSA≤100 | 26 | (12.5) | 17 | (13.5) |
| M1/PSA > 100 | 48 | (23.1) | 22 | (17.5) |
| Information missing | 35 | (16.8) | 15 | (11.9) |
| Gleason score*, n(%) | ||||
| 2-6 | 50 | (41.3) | 41 | (45.6) |
| 7 | 20 | (16.5) | 17 | (18.9) |
| 8-10 | 31 | (25.6) | 26 | (28.9) |
| Information missing | 20 | (16.5) | 6 | (6.7) |
* WHO grade translated into Gleason score G1 = 2-6, G2 = 7, G3 = 8-10 in 42 cases
** Lower urinary tract symptoms.
*** Prostate specific antigen
†Incidentally discovered under investigation for symptoms not related to the urinary tract
‡As classified by the International Union Against Cancer (UICC)